The Importance Of Gardasil : Guarding Against The Human Papilloma Virus

HPV is so common in the United States that nearly all men and women will contract the virus at some point during life (Center for Disease Control and Prevention [CDC], 2017). In the United States, in 2008, it is reported that 3.2 million, or one in four adolescent women, ages 14 to 19 have had or have an STD (Kostas-Polston et al., 2012). The rate of HPV cases has only increased since 2008. The prevalence of a genital infection with any HPV type was 42.5% among United States during 2013–2014 (CDC, 2017). The incidence of HPV in the United States is about 14 million people each year.

The HPV virus has gone unseen by many until the recent controversy over the vaccine. However, this virus is thought to be one of the world’s most wide spread STD’s. “According to the Centers for Disease Control and Prevention (CDC), about 6.2 million women and men are newly infected every year” with HPV. HPV has over 100 strains, with more than thirty that are sexually transmitted. Some of these strains are known to cause cervix, vulva, vagina, anus, or penis cancers and others can cause genital warts. “Studies have found the vaccine to be almost 100% effective in preventing diseases caused by the four HPV types covered by the vaccine—including precancers of the cervix, vulva and vagina, and genital warts” (“HPV Questions and

Prophylactic vaccination against high risk human papilloma virus 16 and 18 represents an exciting means of protection against HPV related malignancy. However, this strategy alone, even if there is a level of cross protection against other oncogenic viruses, cannot completely prevent cervical cancer. In some countries cervical screening programs have reduced the incidence of invasive cervical cancer by up to 80 percent although this decline has now reached a plateau with current cancers occurring in patients who have failed to attend for screening or where the sensitivity of the tests have proved inadequate. Cervical screening is inevitably associated with significant anxiety for the many women who require investigation and treatment following abnormal cervical cytology. However, it is vitally important to stress the need for continued cervical screening to complement vaccination in order to optimize prevention in vaccines and prevent cervical cancer in older women where the value of vaccination is currently unclear. It is likely that vaccination will ultimately change the natural history of HPV disease by reducing the influence of the highly oncogenic types HPV 16 and 18. In the long term this is likely to lead to an increase in recommended screening intervals. HPV vaccination may also reduce

Human Papilloma Virus, more commonly known as HPV, is a sexually transmitted virus. It is spread from skin-to-skin contact with an infected person, typically during sexual encounters. It is the most common sexually transmitted disease in the United States. According to the Immunize Action Coalition, “most sexually active American men and woman will contract at least one type of HPV virus during their lifetime” (A Parent 's Guide to Preteen, 2013, p. 1). To put the numbers in perspective, it infects an estimated seventy-nine million Americans today with approximately fourteen million more people being affected additionally each year (Human

HPV is the number one sexually transmitted infection (STI) in the United States, and anyone who is sexually active is at risk of contracting the virus. HPV is transmitted through intimate skin-to-skin contact with someone who has the virus, and it is so common that most all sexually active men and women encounter a strain without ever knowing they’re infected (CDC). There are many strains of the HPV virus, some of which don’t cause cervical cancer. To help understand and classify the types of HPV, the terms low-risk and high-risk HPV are used. Some

The Human Papillomavirus (HPV) is the most common sexually transmitted infection (STI). There are over 100 types of HPV, but only 40 types affect the genital area and can cause genital warts and cervical cancer in women (“Human Papillomavirus (HPV) Vaccine”). In 2011 in the United States, 12,109 women were diagnosed with cervical cancer. Of those, 4,092 women died (“Cervical Cancer Statistics”). HPV is not only contracted from sexual intercourse, but also from skin to skin contact, including oral sex. The STI affects males and females involved in both homosexual and heterosexual sexual activities. Over 70 percent of sexually active individuals contract and carry HPV before the age of 80. In order to combat HPV two different brands of HPV vaccination – Gardasil and Cervarix – were created. Both include a vaccination plan of three shots over the course of six months. Gardasil was created by Merck & Co., and was licensed by the FDA in June 2006. The vaccine protects against HPV types 16 and 18, which lead to cervical cancer, as well as types 6 and 11, which cause 90% of genital warts. The FDA later approved Cervarix, created by GlaxoSmithKline, in 2009, which only protects against HPV types 16 and 18 (“Human Papillomavirus (HPV) Vaccine”). Originally, Gardasil was only approved for females, but three years after the release, the vaccine was approved

According to the Centers for Disease Control and Prevention (CDC), Human papillomavirus (HPV) infects roughly 20 million individuals in the United States with 6.1 million new cases each year. There is no cure for HPV, only treatment for associated health problems. There are more than 30 strains of HPV that affect more than half of sexually active individuals in their lifetime. Public health risks involve several types of HPV leading to precancerous lesions and causing 70% of cervical cancer. Cervical cancer, the second most common cancer, affects many women globally. In the United States, nearly 10,000 women are diagnosed with cervical cancer annually and 3,700 of those women die. It has been reported by American Cancer Society that with early

Cervical cancer is the leading cause of cancerous death, in women, since 1950. Approximately 200,000 cervical cancer patients die each year in developing countries. Strains like HPV 16 and 18 cause about 70% of cervical cancer in women– one of the top causes of death in the world (WebMD, 2010, p.1). In the Unites States, about 10,000 women acquire the disease and 3,700 die annually Human Papilloma Virus (HPV) is directly associated as a cause of cervical cancer. This virus affects the skin and genital area and, in some cases, it can also infect the throat and mouth. Since the HPV is passed from one person to another through skin-to-skin or sexual contact, sexually active people are more prone to this virus. Merck

Human papilloma virus, or HPV, is a sexually transmitted infection, and the more sex partners someone has, the bigger their risk. Now, a study out this week shows there’s a silent epidemic of HPV-related cancers among men. In fact, the study found that men are more likely to be infected with cancer-causing oral HPV strains than women, suggesting there are more throat cancers in men than cervical cancer in women.

Human Papillomavirus(HPV) is the most common sexually transmitted infection in the United States, according to Centers for Disease Control and Prevention(CDC) around 20 million people are infected with HPV and additional 6.2 million people are newly infected every year. According to National Health and Nutrition Examination Survey in 2003-2004 among sexually active women (57% of 14 to 19 years and 97% of 20 to 59 years) HPV was highest prevalent in youngest age group (40% of 14-19 years and 50% of 20-24 years). Infection rates decrease after age of 24 years. There are more than 100 types of HPV viruses out of which 40 cause genital infections. Out of

In their 2015 study Alves Ribeiro et al. found that women who began having sexual intercourse prior to age of 16 were more than four times as likely to have a HPV infection (OR 4.41; 95%CI:1.20-19.33), and nearly five times as likely for that infection to involve serotypes 16 and 18 (OR 4.68; 95% CI: 1.20-21.32). Moreover, women with a sexual debut prior to age 16 were twice as likely to have a diagnosis of cervical intraepithelial neoplasia (CIN)1 or greater (OR 2.2; 95% CI: 0.94-5.08 CITE 2. The same study also demonstrated a statistically significant association between CIN 1 and HPV infection, especially infection with HPV serotypes 16 and 18 (OR 2.76; 95% CI: 1.05-7.19) and (OR 3.53; 95% CI: 1.17-10.67) respectively (Alves Riberio et al., 2015). Over 90% of females in the United States are sexually active by age 24; correspondingly, the prevalence of high-risk HPV peaks at over 43% in the 20-24 age group (Vegunta, Kransdorf, & Mayer, 2014). By age 30, the prevalence of high-risk HPV decreases to 30.4%, and continues to decrease as age increases. It is thought that this age related decrease in prevalence can be attributed to a combination of factors, including, decreased exposure, resistance to reinfections, and HPV’s self-limiting nature (Alves Ribeiro et al., 2015; Vegunta et al., 2014).

Human Papilloma Virus (HPV) accounts for the third most prevalent cancer in females worldwide,15 as it is the most common sexually transmitted infection (STI).2 There are more than 100 subtypes of HPV; 16 of those subtypes are known to be high-risk.15 HPV is a crucial precursor to cervical cancer in 99.8% of those affected,2 with subtypes 16 and 18 being the most common types.15

Among the many arguments for mandatory HPV vaccination, the foremost is that it is an important medical achievement and a major public health milestone. This vaccine has proven to be one-hundred percent effective in preventing the 4 HPV strains that are responsible for seventy percent of cervical cancers and ninety percent of genital warts. In addition, no serious side effects have been identified. Because this vaccine is a preventive measure, administration before onset of sexual activity is ideal; however, even females who have been sexually active can still benefit from this vaccination (Perkins et al., 2010). Nationally and internationally, the HPV vaccine will significantly reduce disease burden by reducing monetary and psychological costs of invasive procedures that remove precancerous and cancerous lesions. By combining vaccination with routine Pap smear screening, these public health efforts have the remarkable opportunity to eradicate cervical cancer (Ramet et al., 2011).

The Human Papillomavirus (HPV) is the most common sexually transmitted disease in the United States among teens and young adults (Centers for Disease Control and Prevention, 2015). HPV is known to attack epithelial cells and as many as 75% to 80% of males and females can become infected in their lifetime (Merck Sharp & Dohme Corp., 2012). There are many different strains—some of which cause no symptoms and others that can cause genital warts, as well as various types of oropharyngeal and/or anogenital cancers. There are currently three vaccines licensed by the FDA since 2006—Cervarix, Gardasil, and Gardasil 9. These vaccines are a 3-dose series recommended for routine use among girls and boys at ages 11 and 12, and ages 13-26 for those who have not previously been infected. Although these vaccines do not protect against all HPV strains, they do protect against the two most common high-risk (cancer-causing) strains—types 16 and 18. In addition to preventing types 16 and 18, the Gardasil vaccine protects against the two most common low-risk (genital warts-causing) strains and the Gardasil 9 vaccine protects against five additional cancer-causing strains, as well as the other strains previously mentioned. (Centers for Disease Control and Prevention, 2015)The purpose of the Bauldur-Felskov et al (2014) study was to assess the efficacy of the HPV vaccine against cervical lesions by comparing the incidence trends before and after the vaccination program was first implemented.

Prior to June of 2006, Human Pappilomarius (HPV) was almost unheard of to the general public. But after FDA approval of Gardasil manufactured by Merck& Co., HPV vaccine became the headline of many articles and breaking news of many TV channels. Why? Let’s us explore it. According to World Health Organization (WHO), HPV worldwide is the most common sexual transmitted Disease (STD). There are more than 100 strains of HPV and in those 13 strains are known for causing cancer in human. HPV infection goes undetected majority of the time. HPV-infected victims mostly have no signs or symptoms or are there any tests available to detect it. The body immunity usually gets rid of the viruses on its own. However, with persistent infection, it may lead to genital warts and worrisome oro-genital cancers. With normal immunity, it takes about 15-20 years for cervical cancer to develop. Worldwide, cervical cancer is the second most frequent cancer. It is estimated more than 270,000 deaths from cervical cancer annually (1-6). In 2007, to prevent the devastation result of HPV-associated cancer, the National Advisory Committee on Immunization practices (ACIP) recommended Gardasil as a routine vaccination for girl’s ages 11 to 12 with a catch-up vaccination for those aged 13 to 26. Across the country, thereafter, state legislature attempt to make HPV vaccine mandated. As the result, controversy was generated. In this paper, we